Abiopharma

🔍 Pizzie Nick (Executive)

Company: Axsome Therapeutics, Inc. (AXSM)

Report Date: 2026-06-09

Detailed Transactions and Holdings:

• Acquired 33,000 shares of Common Stock at $3.5 per share (Direct)
  Date: 2026-06-09 | Code: M | equity_swap_involved: false | shares_owned_after: 75,867.00 | transaction_form_type: 4 | Footnotes: F1, F5
• Sold 33,000 shares of Common Stock at $240.09 per share (Direct)
  Date: 2026-06-09 | Code: S | equity_swap_involved: false | shares_owned_after: 42,867.00 | transaction_form_type: 4 | Footnotes: F2, F4, F5
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-06-09 | Code: H | nature_of_ownership: See explanation 6 below. | shares_owned_after: 488.00 | Footnotes: F6
• Sold 33,000 shares of Stock Option (Right to Buy) at $3.5 per share (Derivative)
  Date: 2026-06-09 | Code: M | Expires: 2028-05-16 | Exercise: 2019-05-16 | equity_swap_involved: false | shares_owned_after: 72,000.00 | transaction_form_type: 4 | Footnotes: F2

Footnotes:

• F1: Represents an exercise of stock options which was held for over 8 years and exercised prior to the 10-year expiration date of such options.
• F2: Such transaction was pursuant to a pre-approved 10b5-1 plan, which has now been completed.
• F3: Represents the subsequent sale of the underlying shares of the aforementioned exercise of stock options.
• F4: Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $236.46 and $242.35.
• F5: Includes the prior purchase of shares of common stock pursuant to the Issuer's Employee Stock Purchase Plan.
• F6: Represents additional shares indirectly beneficially owned by the reporting person as custodian for his children's UTMA accounts.